B-intervention	0	9	Cediranib
I-intervention	10	12	in
I-intervention	13	24	combination
I-intervention	25	29	with
I-intervention	30	41	fulvestrant
O	42	44	in
O	45	52	hormone
O	52	53	-
O	53	62	sensitive
O	63	73	metastatic
O	74	80	breast
O	81	87	cancer
O	87	88	:
O	89	90	a
O	91	101	randomized
O	102	107	Phase
O	108	110	II
O	111	116	study
O	116	117	.

O	118	125	Hormone
O	126	134	receptor
O	134	135	-
O	135	143	positive
O	144	150	breast
O	151	157	cancer
O	158	160	is
O	161	168	treated
O	169	173	with
O	174	182	estrogen
O	183	193	inhibitors
O	193	194	.

O	195	206	Fulvestrant
O	207	208	(
O	208	216	FASLODEX
O	216	217	™
O	217	218	)
O	218	219	,
O	220	222	an
O	223	231	estrogen
O	232	240	receptor
O	241	242	(
O	242	244	ER
O	244	245	)
O	246	256	antagonist
O	257	261	with
O	262	264	no
O	265	270	known
O	271	278	agonist
O	279	286	effects
O	286	287	,
O	288	301	competitively
O	302	307	binds
O	307	308	,
O	309	315	blocks
O	316	319	and
O	320	328	degrades
O	329	332	the
O	333	335	ER
O	335	336	.

O	337	345	Vascular
O	346	357	endothelial
O	358	364	growth
O	365	371	factor
O	372	373	(
O	373	377	VEGF
O	377	378	)
O	379	382	may
O	383	390	mediate
O	391	401	resistance
O	402	404	to
O	405	407	ER
O	408	419	antagonists
O	419	420	.

O	421	430	Cediranib
O	431	433	is
O	434	435	a
O	436	442	highly
O	443	449	potent
O	450	454	VEGF
O	455	464	signaling
O	465	474	inhibitor
O	475	479	with
O	480	488	activity
O	489	496	against
O	497	500	all
O	501	506	three
O	507	511	VEGF
O	512	521	receptors
O	521	522	.

O	523	527	This
O	528	538	randomized
O	539	544	Phase
O	545	547	II
O	548	553	study
O	554	563	evaluated
O	564	573	cediranib
O	574	578	plus
O	579	590	fulvestrant
O	590	591	.

B-eligibility	592	606	Postmenopausal
I-eligibility	607	612	women
I-eligibility	613	617	with
I-eligibility	618	625	hormone
I-eligibility	625	626	-
I-eligibility	626	635	sensitive
I-eligibility	636	646	metastatic
I-eligibility	647	653	breast
I-eligibility	654	660	cancer
O	661	665	were
O	666	674	eligible
O	674	675	.

O	676	679	The
O	680	687	primary
O	688	696	endpoint
O	697	700	was
B-outcome-Measure	701	712	progression
I-outcome-Measure	712	713	-
I-outcome-Measure	713	717	free
I-outcome-Measure	718	726	survival
I-outcome-Measure	727	728	(
I-outcome-Measure	728	731	PFS
I-outcome-Measure	731	732	)
O	732	733	.

O	734	743	Secondary
O	744	753	endpoints
O	754	762	included
B-outcome-Measure	763	772	objective
I-outcome-Measure	773	781	response
I-outcome-Measure	782	786	rate
I-outcome-Measure	787	788	(
I-outcome-Measure	788	791	ORR
I-outcome-Measure	791	792	)
O	792	793	,
B-outcome-Measure	794	802	duration
I-outcome-Measure	803	805	of
I-outcome-Measure	806	814	response
O	814	815	,
B-outcome-Measure	816	824	clinical
I-outcome-Measure	825	832	benefit
I-outcome-Measure	833	837	rate
I-outcome-Measure	838	839	(
I-outcome-Measure	839	842	CBR
I-outcome-Measure	842	843	)
O	843	844	,
B-outcome-Measure	845	851	safety
I-outcome-Measure	851	852	/
I-outcome-Measure	852	864	tolerability
O	865	868	and
B-outcome-Measure	869	885	pharmacokinetics
I-outcome-Measure	886	887	(
I-outcome-Measure	887	889	PK
I-outcome-Measure	889	890	)
O	890	891	.

O	892	900	Patients
O	901	909	received
O	910	919	cediranib
O	920	922	45
O	923	925	mg
O	925	926	/
O	926	929	day
O	930	931	(
O	931	932	n
O	932	933	=
B-intervention-participants	933	935	31
O	935	936	)
O	937	939	or
B-control	940	947	placebo
O	948	949	(
O	949	950	n
O	950	951	=
B-control-participants	951	953	31
O	953	954	)
O	955	959	both
O	960	964	plus
O	965	976	fulvestrant
O	976	977	.

O	978	989	Demographic
O	989	990	/
O	990	998	baseline
O	999	1014	characteristics
O	1015	1019	were
O	1020	1024	well
O	1025	1033	balanced
O	1033	1034	.

O	1035	1043	Patients
O	1044	1051	treated
O	1052	1056	with
O	1057	1066	cediranib
O	1067	1070	had
O	1071	1072	a
O	1073	1082	numerical
O	1083	1092	advantage
O	1093	1095	in
B-outcome	1096	1099	PFS
O	1100	1101	(
O	1101	1107	hazard
O	1108	1113	ratio
O	1113	1114	=
O	1114	1115	0
O	1115	1116	.
O	1116	1119	867
O	1119	1120	,
O	1121	1122	P
O	1122	1123	=
O	1123	1124	0
O	1124	1125	.
O	1125	1128	669
O	1128	1129	;
O	1130	1136	median
B-iv-cont-median	1137	1140	223
O	1141	1143	vs
O	1143	1144	.
B-cv-cont-median	1145	1148	112
I-cv-cont-median	1149	1153	days
O	1153	1154	,
O	1155	1167	respectively
O	1167	1168	)
O	1169	1172	and
B-outcome	1173	1176	ORR
O	1177	1178	(
B-iv-bin-percent	1178	1180	22
O	1181	1183	vs
O	1183	1184	.
B-cv-bin-percent	1185	1186	8
I-cv-bin-percent	1187	1188	%
O	1188	1189	,
O	1190	1202	respectively
O	1202	1203	)
O	1204	1206	vs
O	1206	1207	.
O	1208	1215	placebo
O	1215	1216	,
O	1217	1225	although
O	1226	1229	not
O	1230	1243	statistically
O	1244	1255	significant
O	1255	1256	.

B-outcome	1257	1260	CBR
O	1261	1264	was
B-iv-bin-percent	1265	1267	42
I-iv-bin-percent	1268	1269	%
O	1270	1272	in
O	1273	1277	both
O	1278	1282	arms
O	1282	1283	.

O	1284	1287	The
O	1288	1292	most
O	1293	1299	common
B-outcome	1300	1307	adverse
I-outcome	1308	1314	events
I-outcome	1315	1316	(
I-outcome	1316	1319	AEs
I-outcome	1319	1320	)
O	1321	1323	in
O	1324	1327	the
O	1328	1337	cediranib
O	1338	1341	arm
O	1342	1346	were
B-outcome	1347	1355	diarrhea
O	1356	1357	(
B-iv-bin-percent	1357	1359	68
I-iv-bin-percent	1360	1361	%
O	1361	1362	)
O	1362	1363	,
B-outcome	1364	1371	fatigue
O	1372	1373	(
B-iv-bin-percent	1373	1375	61
I-iv-bin-percent	1376	1377	%
O	1377	1378	)
O	1379	1382	and
B-outcome	1383	1395	hypertension
O	1396	1397	(
B-iv-bin-percent	1397	1399	55
I-iv-bin-percent	1400	1401	%
O	1401	1402	)
O	1402	1403	.

O	1404	1407	The
B-outcome	1408	1417	incidence
I-outcome	1418	1420	of
I-outcome	1421	1426	grade
I-outcome	1427	1428	≥
I-outcome	1429	1430	3
I-outcome	1431	1434	AEs
O	1435	1436	(
B-iv-bin-percent	1436	1438	68
I-iv-bin-percent	1439	1440	%
O	1441	1443	vs
O	1443	1444	.
B-cv-bin-percent	1445	1447	32
I-cv-bin-percent	1448	1449	%
O	1449	1450	)
O	1450	1451	,
B-outcome	1452	1459	serious
I-outcome	1460	1463	AEs
O	1464	1465	(
B-iv-bin-percent	1465	1467	48
I-iv-bin-percent	1468	1469	%
O	1470	1472	vs
O	1472	1473	.
B-cv-bin-percent	1474	1476	13
I-cv-bin-percent	1477	1478	%
O	1478	1479	)
O	1479	1480	,
B-outcome	1481	1496	discontinuation
I-outcome	1497	1500	AEs
O	1501	1502	(
B-iv-bin-percent	1502	1504	39
I-iv-bin-percent	1505	1506	%
O	1507	1509	vs
O	1509	1510	.
B-cv-bin-percent	1511	1513	10
I-cv-bin-percent	1514	1515	%
O	1515	1516	)
O	1516	1517	,
O	1518	1521	and
B-outcome	1522	1531	cediranib
I-outcome	1532	1536	dose
I-outcome	1537	1547	reductions
I-outcome	1547	1548	/
I-outcome	1548	1561	interruptions
O	1562	1563	(
B-iv-bin-percent	1563	1565	74
I-iv-bin-percent	1566	1567	%
O	1568	1570	vs
O	1570	1571	.
B-cv-bin-percent	1572	1574	32
I-cv-bin-percent	1575	1576	%
O	1576	1577	)
O	1578	1582	were
O	1583	1589	higher
O	1590	1592	in
O	1593	1596	the
O	1597	1606	cediranib
O	1607	1610	arm
O	1610	1611	.

O	1612	1617	There
O	1618	1621	was
O	1622	1624	no
O	1625	1633	evidence
O	1634	1636	of
O	1637	1638	a
O	1639	1649	clinically
O	1650	1658	relevant
O	1659	1665	effect
O	1666	1668	of
O	1669	1678	cediranib
O	1679	1681	on
O	1682	1693	fulvestrant
O	1694	1696	PK
O	1696	1697	.

O	1698	1707	Cediranib
O	1708	1712	plus
O	1713	1724	fulvestrant
O	1725	1728	may
O	1729	1740	demonstrate
O	1741	1749	clinical
O	1750	1758	activity
O	1759	1761	in
O	1762	1766	this
O	1767	1777	population
O	1777	1778	,
O	1779	1782	but
O	1783	1792	cediranib
O	1793	1795	45
O	1796	1798	mg
O	1799	1802	was
O	1803	1806	not
O	1807	1819	sufficiently
O	1820	1824	well
O	1825	1834	tolerated
O	1834	1835	.

O	1836	1849	Investigation
O	1850	1852	of
O	1853	1858	lower
O	1859	1864	doses
O	1865	1867	of
O	1868	1877	cediranib
O	1878	1882	plus
O	1883	1891	hormonal
O	1891	1892	/
O	1892	1904	chemotherapy
O	1905	1910	could
O	1911	1913	be
O	1914	1924	considered
O	1924	1925	.
